Loading…
AIM ImmunoTech Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in AIM.
▼ -99.9% over 5Y.
today you would have $0.97▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.10 | $19.40 | $42.68 | $30.07 | |
| P/S | 88.7x | 38.3x | 74.8x | 103.8x | 102.6x |
| P/B | — | — | — | 2.0x | 0.4x |
| EPS | -$8.62 | -$30.92 | -$59.94 | -$39.96 | |
| Profit margin | -14064.20% | -15861.36% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TRIBTrinity Biotech PLC | $9.68 | — | — | — | — | $7.87M |
| SKYESkye Bioscience, Inc. | $1.78 | — | — | — | -233.87% | $7.86M |
| ICCMIceCure Medical Ltd. | $2.30 | — | 0.7x | — | -228.31% | $7.88M |
| ITOCiTonic Holdings Ltd | $0.32 |
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Company description provided by Yahoo Finance.
| -10188.24% |
| -14337.62% |
| -13790.78% |
| ROE | — | — | — | -283.00% | -50.55% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.9x |
| — |
| -71.25% |
| $7.83M |
| ENSCEnsysce Biosciences, Inc. | $0.40 | — | — | — | -1295.09% | $7.78M |
| AIDX20/20 Biolabs, Inc. | $0.62 | — | 4.7x | — | -331.22% | $7.97M |